Dianne Daniels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dianne Daniels has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
David Last
The Advanced Technology Center, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
22 shared publications- David Guez
Advanced Technology Center, Sheba Medical Center, Ramat-Gan, Israel
17 shared publications Yael Mardor
The Advanced Technology Center, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
17 shared publications- Shirley Sharabi
The Advanced Technology Center, Sheba Medical Center, Ramat-Gan, Israel
15 shared publications - Yael Mardor
The Advanced Technology Center, Sheba Medical Center, Ramat-Gan, Israel
14 shared publications Aharon Ocherashvilli
Advanced Technology Center, Sheba Medical Center, Israel
9 shared publications
Latest Publications
- Open Access
- 5 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Application of treatment response assessment maps (TRAMs), based on delayed-contrast MRI for radiomic characterization of breast lesions
Dynamic contrast-enhanced (DCE) breast MRI is a highly sensitive modality for detecting breast cancer, but its limited specificity often leads to false-positive findings and unnecessary biopsies. Radiomics offers a quantitative approach to improve lesion characterization by capturing tumor-related image-based features. In this study, we explored the application of treatment response assessment maps (TRAMs), a technique based on delayed-contrast MRI originally developed for neuro-oncology, to breast imaging. TRAMs are sensitive to late contrast clearance dynamics influenced by vascular and tissue microenvironment properties. By capturing differences in permeability and contrast retention, TRAMs may enable improved differentiation between malignant tumors and abnormal non-tumor or benign tissues, thus enhancing diagnostic precision in breast MRI. Radiomic features were extracted from post-contrast DCE-MRI phases using fat-suppressed T1-weighted MR images (T1-MRI), capturing the dynamic enhancement patterns of 243 breast lesions. TRAMs were generated by subtracting delayed post-contrast images from early post-contrast images (after image pre-processing), and corresponding TRAMs-based radiomic features were calculated. Various machine learning classifiers were trained to differentiate between malignant and benign lesions. The diagnostic performances were evaluated using area under the curve (AUC), sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), and accuracy, with 95% confidence intervals. TRAMs-based radiomic models yielded diagnostic performance comparable to conventional T1-MRI models across evaluated metrics. While T1-MRI models achieved AUCs between 0.79 and 0.85, several TRAMs feature combinations reached AUC point estimates of 0.87. A univariate model using the TRAMs feature BlueClustV (representing the volume of the largest cluster of pixels showing contrast clearance at the delayed time point) alone achieved an AUC of 0.86, with balanced sensitivity (0.82) and specificity (0.85), demonstrating high diagnostic value using a single interpretable feature. These results were further supported by competitive PPV, NPV, and accuracy values. ROC analysis demonstrated that TRAMs models maintained favorable sensitivity–specificity tradeoffs, with the univariate BlueClustV feature showing the most balanced curve, emphasizing its diagnostic utility in distinguishing malignant from benign lesions. In summary, TRAMs-based classifiers provide complementary physiological information to standard imaging, suggesting their potential to reduce benign biopsies and aid decision making in breast cancer diagnosis.
- 5 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessApplication of treatment response assessment maps (TRAMs), based on delayed-contrast MRI for radiomic characterization of breast lesions
Dynamic contrast-enhanced (DCE) breast MRI is a highly sensitive modality for detecting breast cancer, but its limited specificity often leads to false-positive findings and unnecessary biopsies. Radiomics offers a quantitative approach to improve lesion characterization by capturing tumor-related image-based features. In this study, we explored the application of treatment response assessment maps (TRAMs), a technique based on delayed-contrast MRI originally developed for neuro-oncology, to breast imaging. TRAMs are sensitive to late contrast clearance dynamics influenced by vascular and tissue microenvironment properties. By capturing differences in permeability and contrast retention, TRAMs may enable improved differentiation between malignant tumors and abnormal non-tumor or benign tissues, thus enhancing diagnostic precision in breast MRI. Radiomic features were extracted from post-contrast DCE-MRI phases using fat-suppressed T1-weighted MR images (T1-MRI), capturing the dynamic enhancement patterns of 243 breast lesions. TRAMs were generated by subtracting delayed post-contrast images from early post-contrast images (after image pre-processing), and corresponding TRAMs-based radiomic features were calculated. Various machine learning classifiers were trained to differentiate between malignant and benign lesions. The diagnostic performances were evaluated using area under the curve (AUC), sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), and accuracy, with 95% confidence intervals. TRAMs-based radiomic models yielded diagnostic performance comparable to conventional T1-MRI models across evaluated metrics. While T1-MRI models achieved AUCs between 0.79 and 0.85, several TRAMs feature combinations reached AUC point estimates of 0.87. A univariate model using the TRAMs feature BlueClustV (representing the volume of the largest cluster of pixels showing contrast clearance at the delayed time point) alone achieved an AUC of 0.86, with balanced sensitivity (0.82) and specificity (0.85), demonstrating high diagnostic value using a single interpretable feature. These results were further supported by competitive PPV, NPV, and accuracy values. ROC analysis demonstrated that TRAMs models maintained favorable sensitivity–specificity tradeoffs, with the univariate BlueClustV feature showing the most balanced curve, emphasizing its diagnostic utility in distinguishing malignant from benign lesions. In summary, TRAMs-based classifiers provide complementary physiological information to standard imaging, suggesting their potential to reduce benign biopsies and aid decision making in breast cancer diagnosis.
- 1 February 2024
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 41 (3-4) , 430-446
Application of Delayed Contrast Extravasation Magnetic Resonance Imaging for Depicting Subtle Blood–Brain Barrier Disruption in a Traumatic Brain Injury Model
Background: The blood-brain barrier (BBB) is composed of brain microvasculature that provides selective transport of solutes from the systemic circulation into the central nervous system to protect the brain and spinal microenvironment. Damage to the BBB in the acute phase following traumatic brain injury (TBI) is recognized as a major underlying mechanism leading to secondary long-term damage. However, due to the lack of technological ability to detect subtle BBB disruption (BBBd) in the chronic phase, the presence of chronic BBBd is disputable. Thus, the dynamics and course of long-term BBBd post-TBI remains elusive. Methods: 30 C57BL/6 male mice subjected to TBI using our weight drop closed head injury model and 19 naïve controls were scanned by MRI up to 540 days following injury. BBB maps were calculated from delayed contrast extravasation MRI (DCM) with high spatial resolution and high sensitivity to subtle BBBd, enabling depiction and quantification of BBB permeability. At each time point 2-6 animals were sacrificed and their brains were extracted, sectioned, and stained for BBB biomarkers including: blood microvessel coverage by astrocyte using GFAP, AQP4, ZO-1 gaps and IgG leakage. Results: we found that DCM provided depiction of subtle yet significant BBBd up to 1.5 years following TBI, with significantly higher sensitivity than standard contrast-enhanced T1-weighted and T2-weighted MRI (BBBd volumes main effect DCM/T1/T2 p<0.0001 F(2,70)=107.3, time point p<0.0001 F(2,133, 18.66)=23.53). In 33% of the cases, both in the acute and chronic stages, there was no detectable enhancement on standard T1-MRI, nor detectable hyper-intensities on T2-MRI, whereas DCM showed significant BBBd volumes. BBBd values of TBI mice at the chronic stage were fonud significantly higher compered to age matched naïve animals at 30,60 and 540 days. The calculated BBB maps were histologically validated by determining significant correlation between the calculated levels of disruption and a diverse set of histopathological parameters obtained from different brain regions, presenting different components of the BBB. Summary and Discussion: Cumulative evidence from recent years points to BBBd as a central component of the pathophysiology of TBI. Therefore, it is expected that routine use of highly sensitive non-invasive techniques to measure BBBd, such as DCM with advanced analysis methods, may enhance our understanding of the changes in BBB function following TBI. Application of the DCM technology to other CNS disorders, as well as to normal aging, may shed light on the involvement of chronic subtle BBBd in these conditions.
- 1 February 2024
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 41 (3-4) , 430-446
Application of Delayed Contrast Extravasation Magnetic Resonance Imaging for Depicting Subtle Blood–Brain Barrier Disruption in a Traumatic Brain Injury Model
Background: The blood-brain barrier (BBB) is composed of brain microvasculature that provides selective transport of solutes from the systemic circulation into the central nervous system to protect the brain and spinal microenvironment. Damage to the BBB in the acute phase following traumatic brain injury (TBI) is recognized as a major underlying mechanism leading to secondary long-term damage. However, due to the lack of technological ability to detect subtle BBB disruption (BBBd) in the chronic phase, the presence of chronic BBBd is disputable. Thus, the dynamics and course of long-term BBBd post-TBI remains elusive. Methods: 30 C57BL/6 male mice subjected to TBI using our weight drop closed head injury model and 19 naïve controls were scanned by MRI up to 540 days following injury. BBB maps were calculated from delayed contrast extravasation MRI (DCM) with high spatial resolution and high sensitivity to subtle BBBd, enabling depiction and quantification of BBB permeability. At each time point 2-6 animals were sacrificed and their brains were extracted, sectioned, and stained for BBB biomarkers including: blood microvessel coverage by astrocyte using GFAP, AQP4, ZO-1 gaps and IgG leakage. Results: we found that DCM provided depiction of subtle yet significant BBBd up to 1.5 years following TBI, with significantly higher sensitivity than standard contrast-enhanced T1-weighted and T2-weighted MRI (BBBd volumes main effect DCM/T1/T2 p<0.0001 F(2,70)=107.3, time point p<0.0001 F(2,133, 18.66)=23.53). In 33% of the cases, both in the acute and chronic stages, there was no detectable enhancement on standard T1-MRI, nor detectable hyper-intensities on T2-MRI, whereas DCM showed significant BBBd volumes. BBBd values of TBI mice at the chronic stage were fonud significantly higher compered to age matched naïve animals at 30,60 and 540 days. The calculated BBB maps were histologically validated by determining significant correlation between the calculated levels of disruption and a diverse set of histopathological parameters obtained from different brain regions, presenting different components of the BBB. Summary and Discussion: Cumulative evidence from recent years points to BBBd as a central component of the pathophysiology of TBI. Therefore, it is expected that routine use of highly sensitive non-invasive techniques to measure BBBd, such as DCM with advanced analysis methods, may enhance our understanding of the changes in BBB function following TBI. Application of the DCM technology to other CNS disorders, as well as to normal aging, may shed light on the involvement of chronic subtle BBBd in these conditions.
- Open Access
- 27 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 169
Non-Invasive Low Pulsed Electrical Fields for Inducing BBB Disruption in Mice—Feasibility Demonstration
The blood–brain barrier (BBB) is a major hurdle for the treatment of central nervous system disorders, limiting passage of both small and large therapeutic agents from the blood stream into the brain. Thus, means for inducing BBB disruption (BBBd) are urgently needed. Here, we studied the application of low pulsed electrical fields (PEFs) for inducing BBBd in mice. Mice were treated by low PEFs using electrodes pressed against both sides of the skull (100–400 square 50 µs pulses at 4 Hz with different voltages). BBBd as a function of treatment parameters was evaluated using MRI-based treatment response assessment maps (TRAMs) and Evans blue extravasation. A 3D numerical model of the mouse brain and electrodes was constructed using finite element software, simulating the electric fields distribution in the brain and ensuring no significant temperature elevation. BBBd was demonstrated immediately after treatment and significant linear regressions were found between treatment parameters and the extent of BBBd. The maximal induced electric field in the mice brains, calculated by the numerical model, ranged between 62.4 and 187.2 V/cm for the minimal and maximal applied voltages. These results demonstrate the feasibility of inducing significant BBBd using non-invasive low PEFs, well below the threshold for electroporation.
- 27 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 169
Open AccessNon-Invasive Low Pulsed Electrical Fields for Inducing BBB Disruption in Mice—Feasibility Demonstration
The blood–brain barrier (BBB) is a major hurdle for the treatment of central nervous system disorders, limiting passage of both small and large therapeutic agents from the blood stream into the brain. Thus, means for inducing BBB disruption (BBBd) are urgently needed. Here, we studied the application of low pulsed electrical fields (PEFs) for inducing BBBd in mice. Mice were treated by low PEFs using electrodes pressed against both sides of the skull (100–400 square 50 µs pulses at 4 Hz with different voltages). BBBd as a function of treatment parameters was evaluated using MRI-based treatment response assessment maps (TRAMs) and Evans blue extravasation. A 3D numerical model of the mouse brain and electrodes was constructed using finite element software, simulating the electric fields distribution in the brain and ensuring no significant temperature elevation. BBBd was demonstrated immediately after treatment and significant linear regressions were found between treatment parameters and the extent of BBBd. The maximal induced electric field in the mice brains, calculated by the numerical model, ranged between 62.4 and 187.2 V/cm for the minimal and maximal applied voltages. These results demonstrate the feasibility of inducing significant BBBd using non-invasive low PEFs, well below the threshold for electroporation.
- 1 August 2020
- Published by Elsevier in Bioelectrochemistry
- Vol. 134, 107521
The effects of point-source electroporation on the blood-brain barrier and brain vasculature in rats: An MRI and histology study
- 1 August 2020
- Published by Elsevier in Bioelectrochemistry
- Vol. 134, 107521
The effects of point-source electroporation on the blood-brain barrier and brain vasculature in rats: An MRI and histology study
- Open Access
- 7 February 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-12
The application of point source electroporation and chemotherapy for the treatment of glioma: a randomized controlled rat study
The prognosis of Glioblastoma Multiforme patients is poor despite aggressive therapy. Reasons include poor chemotherapy penetration across the blood-brain barrier and tumor infiltration into surrounding tissues. Here we studied the effects of combined point-source electroporation (EP) and systemic chemotherapy in glioma-bearing rats. 128 rats were studied. Treatment groups were administered systemic Cisplatin/Methotrexate before EP (either 90 or 180 pulses). Control groups were treated by EP, chemotherapy, or no treatment. Tumor volumes were determined by MRI. Tumors growth rates of the EP + Methotrexate group (1.02 ± 0.77) were significantly lower (p < 0.01) than the control (5.2 ± 1.0) 1-week post treatment. No significant difference was found compared to Methotrexate (1.7 ± 0.5). Objective response rates (ORR) were 40% and 57% for the Methotrexate and EP + Methotrexate groups respectively. Tumor growth rates and ORR of the EP + Cisplatin groups (90 pulses 0.98 ± 0.2, 57%, 180 pulses 1.2 ± 0.1, 33%) were significantly smaller than the control (6.4 ± 1.0, p < 0.01, p < 0.02, 0%) and Cisplatin (3.9 ± 1.0, p < 0.04, p < 0.05, 13%) groups. No significant differences were found between the control groups. Increased survival was found in the EP + Cisplatin group, Χ2 = 7.54, p < 0.006 (Log Rank). Point-source EP with systemic chemotherapy is a rapid, minimal-invasive treatment that was found to induce significant antineoplastic effects in a rat glioma model.
- 7 February 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-12
Open AccessThe application of point source electroporation and chemotherapy for the treatment of glioma: a randomized controlled rat study
The prognosis of Glioblastoma Multiforme patients is poor despite aggressive therapy. Reasons include poor chemotherapy penetration across the blood-brain barrier and tumor infiltration into surrounding tissues. Here we studied the effects of combined point-source electroporation (EP) and systemic chemotherapy in glioma-bearing rats. 128 rats were studied. Treatment groups were administered systemic Cisplatin/Methotrexate before EP (either 90 or 180 pulses). Control groups were treated by EP, chemotherapy, or no treatment. Tumor volumes were determined by MRI. Tumors growth rates of the EP + Methotrexate group (1.02 ± 0.77) were significantly lower (p < 0.01) than the control (5.2 ± 1.0) 1-week post treatment. No significant difference was found compared to Methotrexate (1.7 ± 0.5). Objective response rates (ORR) were 40% and 57% for the Methotrexate and EP + Methotrexate groups respectively. Tumor growth rates and ORR of the EP + Cisplatin groups (90 pulses 0.98 ± 0.2, 57%, 180 pulses 1.2 ± 0.1, 33%) were significantly smaller than the control (6.4 ± 1.0, p < 0.01, p < 0.02, 0%) and Cisplatin (3.9 ± 1.0, p < 0.04, p < 0.05, 13%) groups. No significant differences were found between the control groups. Increased survival was found in the EP + Cisplatin group, Χ2 = 7.54, p < 0.006 (Log Rank). Point-source EP with systemic chemotherapy is a rapid, minimal-invasive treatment that was found to induce significant antineoplastic effects in a rat glioma model.
- Open Access
- 1 February 2019
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 15, 1-6
Radiation-induced vascular malformations in the brain, mimicking tumor in MRI-based treatment response assessment maps (TRAMs)
- 1 February 2019
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 15, 1-6
Open AccessRadiation-induced vascular malformations in the brain, mimicking tumor in MRI-based treatment response assessment maps (TRAMs)
- Open Access
- 1 January 2019
- Published by Taylor & Francis in Drug Delivery
- Vol. 26 (1) , 459-469
Transient blood–brain barrier disruption is induced by low pulsed electrical fields in vitro: an analysis of permeability and trans-endothelial electric resistivity
The blood–brain barrier (BBB) is limiting transcellular and paracellular movement of molecules and cells, controls molecular traffic, and keeps out toxins. However, this protective function is the major hurdle for treating brain diseases such as brain tumors, Parkinson’s disease, Alzheimer’s disease, etc. It was previously demonstrated that high pulsed electrical fields (PEFs) can disrupt the BBB by inducing electroporation (EP) which increases the permeability of the transcellular route. Our goal was to study the effects of low PEFs, well below the threshold of EP on the integrity and function of the BBB. Ten low voltage pulses (5–100 V) were applied to a human in vitro BBB model. Changes in permeability to small molecules (NaF) were studied as well as changes in impedance spectrum and trans-endothelial electric resistivity. Viability and EP were evaluated by Presto-Blue and endogenous Lactate dehydrogenase release assays. The effect on tight junction and adherent junction protein was also studied. The results of low voltage experiments were compared to high voltage experiments (200–1400 V). A significant increase in permeability was found at voltages as low as 10 V despite EP only occurring from 100 V. The changes in permeability as a function of applied voltage were fitted to an inverse-exponential function, suggesting a plateau effect. Staining of VE-cadherin showed specific changes in protein expression. The results indicate that low PEFs can transiently disrupt the BBB by affecting the paracellular route, although the mechanism remains unclear.
- 1 January 2019
- Published by Taylor & Francis in Drug Delivery
- Vol. 26 (1) , 459-469
Open AccessTransient blood–brain barrier disruption is induced by low pulsed electrical fields in vitro: an analysis of permeability and trans-endothelial electric resistivity
The blood–brain barrier (BBB) is limiting transcellular and paracellular movement of molecules and cells, controls molecular traffic, and keeps out toxins. However, this protective function is the major hurdle for treating brain diseases such as brain tumors, Parkinson’s disease, Alzheimer’s disease, etc. It was previously demonstrated that high pulsed electrical fields (PEFs) can disrupt the BBB by inducing electroporation (EP) which increases the permeability of the transcellular route. Our goal was to study the effects of low PEFs, well below the threshold of EP on the integrity and function of the BBB. Ten low voltage pulses (5–100 V) were applied to a human in vitro BBB model. Changes in permeability to small molecules (NaF) were studied as well as changes in impedance spectrum and trans-endothelial electric resistivity. Viability and EP were evaluated by Presto-Blue and endogenous Lactate dehydrogenase release assays. The effect on tight junction and adherent junction protein was also studied. The results of low voltage experiments were compared to high voltage experiments (200–1400 V). A significant increase in permeability was found at voltages as low as 10 V despite EP only occurring from 100 V. The changes in permeability as a function of applied voltage were fitted to an inverse-exponential function, suggesting a plateau effect. Staining of VE-cadherin showed specific changes in protein expression. The results indicate that low PEFs can transiently disrupt the BBB by affecting the paracellular route, although the mechanism remains unclear.
- 1 January 2019
- Published by Elsevier in Brain Stimulation
- Vol. 12 (1) , 1-8
Non-thermal focused ultrasound induced reversible reduction of essential tremor in a rat model
- 1 January 2019
- Published by Elsevier in Brain Stimulation
- Vol. 12 (1) , 1-8
Non-thermal focused ultrasound induced reversible reduction of essential tremor in a rat model
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi183
NIMG-35. TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs) SENSITIVITY TO TUMOR/TREATMENT-EFFECTS AS A FUNCTION OF DATA ACQUISITION PARAMETERS
TRAMs calculated from delayed-contrast MRI enable reliable (sensitivity/specificity>70%) differentiation between tumor (blue in the TRAMs) and non-tumoral tissues (red). The TRAMs are calculated by subtracting 3D T1-MRIs acquired 5min (early time point) post-contrast injection from those acquired 60-105min (late point) later. Here we studied the sensitivity to tumor/treatment-effects as a function of the early T1-MRI acquisition time. 7 patients with high grade glioma and 6 with brain metastases were scanned by the standard TRAMs protocol with the addition of a rapid 3D T1-MRI sequence (20 sec) acquired 2, 5, 12, 17, 20, 24 and 70 min post-contrast. Rapid-TRAMs were calculated using the rapid T1-MRIs, where the late time point was fixed at 70 min and the early time point changed from 2 to 24 min post-contrast. Enhancing volumes were determined on the T1-MRIs and copied to the TRAMs. Blue/tumor and red/treatment-effects volumes were calculated within the enhancing regions. The blue/tumor volumes, calculated from the rapid-TRAMs, increased by a factor of 4.4 ± 2.6 when moving the early time point from 2min to 15.7 ± 2.2min, where they plateaued. The increase between 5min (standard) and 15.7min was by 1.5 ± 0.3. In contrast, when moving from 2 min to 15.7min the red/treatment-effects volumes decreased by 0.7 ± 0.2, and by 0.8 ± 0.1 when moving from 5min. CONCLUSIONS: The TRAMs were shown to provide reliable differentiation between tumor/treatment-effects. The early time point is fixed at 5min post-contrast. Using shorter delays may significantly decrease the sensitivity to tumor. Still, increasing the delay to 15min may increase the sensitivity to tumor. This over-estimation of the tumor volume may be explained by the tumor vasculature clearing contrast diffusing into further brain regions surrounding the tumor. An additional 3D-T1 acquired at 15min may be applied for calculating additional TRAMs with higher sensitivity to tumor, for depicting small tumor regions.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi183
NIMG-35. TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs) SENSITIVITY TO TUMOR/TREATMENT-EFFECTS AS A FUNCTION OF DATA ACQUISITION PARAMETERS
TRAMs calculated from delayed-contrast MRI enable reliable (sensitivity/specificity>70%) differentiation between tumor (blue in the TRAMs) and non-tumoral tissues (red). The TRAMs are calculated by subtracting 3D T1-MRIs acquired 5min (early time point) post-contrast injection from those acquired 60-105min (late point) later. Here we studied the sensitivity to tumor/treatment-effects as a function of the early T1-MRI acquisition time. 7 patients with high grade glioma and 6 with brain metastases were scanned by the standard TRAMs protocol with the addition of a rapid 3D T1-MRI sequence (20 sec) acquired 2, 5, 12, 17, 20, 24 and 70 min post-contrast. Rapid-TRAMs were calculated using the rapid T1-MRIs, where the late time point was fixed at 70 min and the early time point changed from 2 to 24 min post-contrast. Enhancing volumes were determined on the T1-MRIs and copied to the TRAMs. Blue/tumor and red/treatment-effects volumes were calculated within the enhancing regions. The blue/tumor volumes, calculated from the rapid-TRAMs, increased by a factor of 4.4 ± 2.6 when moving the early time point from 2min to 15.7 ± 2.2min, where they plateaued. The increase between 5min (standard) and 15.7min was by 1.5 ± 0.3. In contrast, when moving from 2 min to 15.7min the red/treatment-effects volumes decreased by 0.7 ± 0.2, and by 0.8 ± 0.1 when moving from 5min. CONCLUSIONS: The TRAMs were shown to provide reliable differentiation between tumor/treatment-effects. The early time point is fixed at 5min post-contrast. Using shorter delays may significantly decrease the sensitivity to tumor. Still, increasing the delay to 15min may increase the sensitivity to tumor. This over-estimation of the tumor volume may be explained by the tumor vasculature clearing contrast diffusing into further brain regions surrounding the tumor. An additional 3D-T1 acquired at 15min may be applied for calculating additional TRAMs with higher sensitivity to tumor, for depicting small tumor regions.
- 1 May 2018
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 44 (5) , 1022-1030
Focused Ultrasound-Induced Suppression of Auditory Evoked Potentials in Vivo
- 1 May 2018
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 44 (5) , 1022-1030
Focused Ultrasound-Induced Suppression of Auditory Evoked Potentials in Vivo